천식 치료 시장 예측(2026-2032년)

The Asthma Therapeutics Market is projected to grow by USD 42.07 billion at a CAGR of 5.84% by 2032.

Asthma therapeutics are entering a more precision-driven era as clinicians, payers, and public health systems respond to the continuing burden of a chronic inflammatory airway disease that affects children and adults worldwide. Verified global health evidence identifies asthma as a major noncommunicable respiratory condition associated with wheeze, breathlessness, chest tightness, cough, emergency visits, lost productivity, and avoidable mortality when symptoms are uncontrolled. The therapeutic landscape spans inhaled corticosteroids, long-acting bronchodilators, leukotriene pathway modifiers, short-acting relievers, combination inhalers, oral corticosteroids for exacerbations, and targeted biologics for severe asthma phenotypes. Current clinical guidance increasingly emphasizes anti-inflammatory reliever strategies, adherence optimization, correct inhaler technique, personalized stepwise treatment, and risk reduction for exacerbations rather than symptom relief alone. SEO-relevant industry themes shaping asthma therapeutics include severe asthma biologics, eosinophilic asthma treatment, allergic asthma management, inhaled corticosteroid adherence, smart inhalers, digital respiratory care, pediatric asthma therapy, and value-based respiratory disease management.

Transformative Shifts in the Asthma Therapeutics Landscape

The asthma therapeutics landscape is being reshaped by clinical, regulatory, technological, and environmental shifts. A central transformation is the movement from one-size-fits-all bronchodilation toward phenotype- and biomarker-informed care, including the use of blood eosinophils, immunoglobulin E status, fractional exhaled nitric oxide, exacerbation history, comorbidities, and treatment response to guide therapy selection in severe asthma. Guidelines increasingly discourage reliance on short-acting beta agonist-only treatment because overuse is associated with higher exacerbation risk, while inhaled corticosteroid-containing regimens remain foundational for reducing airway inflammation. Another major shift is the expansion of biologic therapies targeting type 2 inflammation pathways, supporting treatment of patients with severe uncontrolled asthma who remain symptomatic despite optimized inhaled therapy. At the same time, digital inhalers, connected nebulization systems, remote monitoring, and electronic adherence tools are changing how clinicians identify poor technique, nonadherence, and worsening control. Environmental and occupational triggers, air pollution, climate-related allergen exposure, viral respiratory infections, tobacco smoke exposure, and indoor air quality continue to influence disease control, making asthma therapeutics increasingly linked to prevention, diagnostics, and population health interventions.

Cumulative Impact of Artificial Intelligence on Asthma Therapeutics

Artificial intelligence is creating cumulative impact across asthma therapeutics by improving diagnosis support, risk stratification, inhaler adherence monitoring, clinical trial design, and real-world evidence generation. AI-enabled algorithms can analyze electronic health records, pharmacy refill patterns, spirometry results, symptom diaries, claims data, wearable signals, and environmental exposure information to identify patients at elevated risk of exacerbations or poor control. In clinical development, machine learning supports biomarker discovery, patient enrichment for severe asthma trials, protocol optimization, and analysis of heterogeneous treatment response across phenotypes such as eosinophilic, allergic, non-type 2, exercise-induced, and pediatric asthma. In care delivery, AI-powered digital respiratory platforms can help detect reliever overuse, missed controller doses, abnormal peak-flow trends, and seasonal trigger patterns, enabling earlier therapeutic adjustment. However, the impact of AI depends on validated models, representative datasets, transparent clinical decision support, cybersecurity safeguards, and workflow integration. For asthma therapeutics, the highest-value AI applications are those that improve evidence-based prescribing, reduce preventable exacerbations, support equitable access to specialist-level insights, and strengthen long-term disease control without replacing clinician judgment.

Key Regional Insights for Asthma Therapeutics

Asia-Pacific is a critical asthma therapeutics region due to its large population base, urbanization, air pollution exposure, expanding healthcare infrastructure, and rising demand for both controller inhalers and severe asthma specialty care. Countries across the region face varied access to spirometry, inhaled corticosteroids, biologics, and respiratory specialists, making affordability and guideline implementation central priorities. North America is characterized by established asthma guidelines, broad availability of inhaled combination therapy, biologic treatment pathways for severe asthma, high adoption of digital health tools, and strong emphasis on payer evidence, adherence, and exacerbation reduction. Latin America shows growing attention to asthma control, but therapeutic outcomes are influenced by unequal access to diagnostics, controller medicines, specialist care, and patient education, particularly across underserved urban and rural communities. Europe benefits from structured respiratory care pathways, strong regulatory oversight, environmental health policy engagement, and increasing use of biomarkers to guide severe asthma treatment decisions. The Middle East faces asthma management challenges linked to dust exposure, climate conditions, urban development, smoking-related respiratory risk, and variability in access to advanced therapies, while investment in specialized care is improving disease management capacity. Africa carries a substantial need for improved asthma diagnosis, essential inhaled medicines, healthcare worker training, and patient education, with outcomes often affected by underdiagnosis, affordability barriers, limited pulmonary function testing, and competing health system priorities.

Key Group Insights for Asthma Therapeutics

Within ASEAN, asthma therapeutics demand is shaped by rapid urbanization, air quality concerns, diverse reimbursement environments, and the need to expand access to inhaled corticosteroid-containing treatment while improving inhaler technique and adherence. GCC countries are advancing respiratory care through specialist clinics, digital health investment, and greater availability of advanced therapies, although environmental dust, heat, and indoor allergen exposure remain important contributors to asthma symptoms. The European Union supports asthma therapeutics through harmonized medicine regulation, pharmacovigilance, health technology assessment, environmental policy, and guideline-based care, with strong emphasis on reducing exacerbations and optimizing severe asthma biologic use through appropriate patient selection. BRICS economies reflect a mixed asthma therapeutic environment: large patient populations, expanding domestic healthcare capacity, uneven access to controller medicines, increasing clinical research participation, and growing demand for affordable inhalers and biologic alternatives where clinically appropriate. G7 countries generally demonstrate higher availability of advanced diagnostics, controller therapies, biologics, digital adherence tools, and real-world evidence systems, making them important settings for evaluating value-based asthma care. NATO member countries overlap significantly with high-income respiratory care systems in North America and Europe, where supply chain resilience, medicine access, health security, and standardized clinical pathways influence continuity of asthma therapeutics during public health disruptions.

Key Country Insights for Asthma Therapeutics

The United States has a highly developed asthma therapeutics ecosystem with broad use of inhaled corticosteroid combinations, biologics for severe asthma, digital adherence solutions, and payer-driven utilization management focused on clinical eligibility and outcomes. Canada emphasizes guideline-based asthma control, primary care integration, and equitable medicine access across provinces, with attention to severe asthma referral pathways and environmental triggers. Mexico continues to prioritize improved diagnosis, access to controller inhalers, and asthma education, especially where out-of-pocket costs and variable specialist availability affect continuity of care. Brazil combines a large respiratory disease burden with public health initiatives and demand for affordable inhaled medicines, while severe asthma care is increasingly shaped by specialist centers and biologic access criteria. The United Kingdom supports evidence-based asthma management through national clinical guidance, quality improvement programs, and attention to preventable asthma deaths, inhaler technique, and appropriate anti-inflammatory therapy. Germany benefits from structured care, specialist access, pulmonary diagnostics, and robust reimbursement review processes for advanced therapies. France emphasizes coordinated respiratory care, pharmacovigilance, and severe asthma assessment using biomarkers and exacerbation history. Russia faces regional variability in access to advanced diagnostics and biologics while maintaining demand for essential inhaled therapies. Italy and Spain have strong respiratory specialist networks, guideline adoption, and growing focus on severe asthma phenotyping, adherence, and reducing oral corticosteroid burden. China is expanding asthma diagnosis and treatment capacity amid urban air quality challenges, increasing hospital-based respiratory care, and broader adoption of controller therapy. India shows substantial need for affordable inhaled medicines, improved diagnosis, patient education, and management of pollution-related respiratory triggers. Japan has advanced respiratory diagnostics, strong clinical guideline use, and access to biologics for eligible severe asthma patients. Australia emphasizes national asthma strategies, inhaler technique education, allergy-linked care, and digital health support across primary and specialist settings. South Korea combines advanced healthcare infrastructure, specialist respiratory services, and growing use of precision treatment approaches for uncontrolled and severe asthma.

Actionable Recommendations for Asthma Therapeutics Leaders

Industry leaders should prioritize asthma therapeutics strategies that improve measurable disease control, reduce exacerbations, and expand equitable access to evidence-based care. Product portfolios should support the full treatment continuum, from affordable inhaled corticosteroid-containing therapy and combination inhalers to targeted biologics for severe asthma phenotypes. Clinical and commercial teams should align with current guideline trends, especially the reduced role of reliever-only treatment and the importance of anti-inflammatory therapy. Investment in patient support should focus on inhaler technique, adherence, refill continuity, trigger avoidance, and shared decision-making, as these factors directly influence real-world outcomes. Developers of digital respiratory tools should validate AI and connected inhaler solutions in diverse populations and integrate outputs into clinician workflows. For advanced therapies, leaders should strengthen biomarker testing pathways, referral networks, real-world evidence programs, and health economic dossiers that demonstrate reductions in exacerbations, emergency visits, oral corticosteroid exposure, and quality-of-life impairment. Supply chain planning should account for essential inhaler availability, cold-chain requirements for biologics, regulatory variability, and access barriers in low- and middle-income settings.

Research Methodology for Asthma Therapeutics Analysis

The research approach for evaluating asthma therapeutics should combine verified secondary research, clinical guideline review, regulatory analysis, and structured expert interpretation. Reliable sources include peer-reviewed respiratory medicine journals, global health agencies, national asthma programs, drug regulatory authorities, clinical trial registries, pharmacovigilance databases, reimbursement guidance, and public health datasets. The methodology should assess therapeutic classes, mechanisms of action, patient phenotypes, prescribing trends, safety considerations, access conditions, and evidence on exacerbation reduction and disease control. Regional and country insights should be validated against healthcare infrastructure indicators, medicine access policies, diagnostic capacity, environmental risk factors, and treatment guideline adoption. Artificial intelligence and digital health analysis should include model validation, real-world usability, data privacy, interoperability, and clinical relevance. To maintain objectivity, the research process should exclude unsupported claims, avoid speculative market sizing or forecasting, and rely on triangulated evidence from credible medical, regulatory, and public health sources.

Conclusion

Asthma therapeutics are moving toward precision care, integrated disease management, and outcome-focused treatment models. The most important shifts include greater use of inhaled corticosteroid-containing regimens, reduced dependence on reliever-only approaches, expansion of biologics for severe uncontrolled asthma, and adoption of digital and AI-enabled tools to improve adherence, risk prediction, and clinical decision support. Regional differences remain substantial, particularly in access to diagnostics, controller medicines, biologics, specialist care, and patient education. Industry participants that align innovation with guideline-based care, affordability, real-world effectiveness, and equitable access will be better positioned to support clinicians and improve patient outcomes. The future of asthma therapeutics will be defined not only by new drug mechanisms but also by the ability to deliver the right therapy to the right patient at the right time, while reducing preventable exacerbations and long-term disease burden.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Asthma Therapeutics Market, by Product Type

• 7.1. Introduction
• 7.2. Biologics
  • 7.2.1. Anti-Ige
  • 7.2.2. Anti-Il5
• 7.3. Inhalers
  • 7.3.1. Dry Powder Inhalers
  • 7.3.2. Metered Dose Inhalers
  • 7.3.3. Soft Mist Inhalers
• 7.4. Nebulizers
  • 7.4.1. Jet Nebulizers
  • 7.4.2. Mesh Nebulizers
  • 7.4.3. Ultrasonic Nebulizers
• 7.5. Oral Drugs
  • 7.5.1. Leukotriene Modifiers
  • 7.5.2. Oral Corticosteroids
  • 7.5.3. Theophylline

8. Asthma Therapeutics Market, by Asthma Type

• 8.1. Introduction
• 8.2. Allergic Asthma
• 8.3. Non-allergic Asthma
• 8.4. Eosinophilic Asthma
• 8.5. Occupational Asthma

9. Asthma Therapeutics Market, by Drug Class

• 9.1. Introduction
• 9.2. Beta Agonists
• 9.3. Combination Therapies
• 9.4. Inhaled Corticosteroids
• 9.5. Leukotriene Modifiers
• 9.6. Monoclonal Antibodies

10. Asthma Therapeutics Market, by Route Of Administration

• 10.1. Introduction
• 10.2. Inhalation
• 10.3. Oral
  • 10.3.1. Tablets
  • 10.3.2. Capsules
  • 10.3.3. Syrups
• 10.4. Injectable
  • 10.4.1. Intravenous
  • 10.4.2. Subcutaneous
  • 10.4.3. Intramuscular

11. Asthma Therapeutics Market, by Therapy Type

• 11.1. Introduction
• 11.2. Maintenance Therapy
• 11.3. Rescue Therapy

12. Asthma Therapeutics Market, by Patient Type

• 12.1. Introduction
• 12.2. Pediatric
• 12.3. Adult
• 12.4. Geriatric

13. Asthma Therapeutics Market, by End User

• 13.1. Introduction
• 13.2. Hospitals
• 13.3. Specialty Clinics
• 13.4. Homecare Settings
• 13.5. Ambulatory Care Centers

14. Asthma Therapeutics Market, by Distribution Channel

• 14.1. Introduction
• 14.2. Hospital Pharmacy
• 14.3. Online Pharmacy
• 14.4. Retail Pharmacy

15. Asthma Therapeutics Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Asthma Therapeutics Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Asthma Therapeutics Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Share Analysis, 2025
• 18.2. FPNV Positioning Matrix, 2025
• 18.3. Market Concentration Analysis, 2025
  • 18.3.1. Concentration Ratio (CR)
  • 18.3.2. Herfindahl Hirschman Index (HHI)
• 18.4. Recent Developments & Impact Analysis, 2025
• 18.5. Product Portfolio Analysis, 2025
• 18.6. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Abbott Laboratories
• 19.2. AbbVie Inc.
• 19.3. Almirall S.A.
• 19.4. Amgen Inc.
• 19.5. Areteia Therapeutics
• 19.6. AstraZeneca PLC
• 19.7. Aurobindo Pharma Limited
• 19.8. Boehringer Ingelheim International GmbH
• 19.9. Chiesi Farmaceutici S.p.A.
• 19.10. Cipla Limited
• 19.11. F. Hoffmann-La Roche Ltd.
• 19.12. Glenmark Pharmaceuticals Ltd.
• 19.13. GSK plc
• 19.14. Hikma Pharmaceuticals PLC
• 19.15. Innoviva Inc.
• 19.16. Johnson & Johnson Services, Inc.
• 19.17. Lupin Limited
• 19.18. Merck & Co. Inc.
• 19.19. Mundipharma International Limited
• 19.20. Novartis AG
• 19.21. Orion Corporation
• 19.22. Pfizer Inc.
• 19.23. Regeneron Pharmaceuticals Inc.
• 19.24. Sanofi S.A.
• 19.25. Sun Pharmaceutical Industries Ltd.
• 19.26. Teva Pharmaceutical Industries Ltd.
• 19.27. Theravance Biopharma Inc.
• 19.28. Vectura Group plc
• 19.29. Verona Pharma plc
• 19.30. Viatris Inc.